6974-56-7

Usage

Uses

Given the limited information on the specific uses, biological effects, or potential hazards of 2-chloro-N-(2,4-dichlorophenyl)acetamide, it is challenging to list its applications comprehensively. However, based on its chemical structure and functional groups, we can infer possible uses in various industries:
Used in Pharmaceutical Industry:
2-Chloro-N-(2,4-dichlorophenyl)acetamide could be used as an intermediate in the synthesis of pharmaceutical compounds for [specific medical conditions or treatments], due to its unique structural features and the presence of chlorine atoms, which may impart specific biological activities.
Used in Chemical Synthesis:
In the chemical synthesis industry, 2-chloro-N-(2,4-dichlorophenyl)acetamide may serve as a building block or reactant in the production of other organic compounds, such as agrochemicals, dyes, or polymers, owing to its amide and chlorinated benzene functionalities.
Used in Research and Development:
2-Chloro-N-(2,4-dichlorophenyl)acetamide could be utilized in research settings to study the effects of chlorinated benzene derivatives on various chemical and biological processes, potentially leading to the discovery of new applications or understanding of its properties.

InChI:InChI=1/C8H6Cl3NO/c9-4-8(13)12-7-2-1-5(10)3-6(7)11/h1-3H,4H2,(H,12,13)

Upstream product

• 587-65-5 N-chloroacetyl-aniline 
• 4015-58-1 monochloroacetic acid anhydride 
• 554-00-7 2,4-Dichloroaniline 
• 71-43-2 benzene 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 104911-88-8 N,N-diethyl-glycine-(2,4-dichloro-anilide) 
• 125983-15-5 (2,4-Dichloro-phenylamino)-oxo-dithioacetic acid methyl ester 
• 92291-38-8 <2-Amino-phenylmercapto>-essigsaeure-<2,4-dichlor-anilid> 
• 92436-27-6 (2-Carbamoyl-phenylmercapto)-essigsaeure-(2,4-dichlor-anilid) 
• 39190-19-7 N-(2,4-dichlorophenyl)benzo[d]oxazol-2-amine 
• 153567-87-4 [(2,4-dichloro-phenylcarbamoyl)-methyl]-phosphonic acid diethyl ester 
• 21507-89-1 3-Hydroxy-benzo[b]thiophene-2-carboxylic acid (2,4-dichloro-phenyl)-amide 
• 81112-76-7 N-(2,4-Dichloro-phenyl)-2-piperidin-1-yl-acetamide 

Relevant academic research and scientific papers

Triazole sulfonamides derivatives and their use in agriculture

The invention provides a novel triazole sulfonamide derivative and application thereof in agriculture. , The invention relates to a triazole sulfonamides derivative as shown in a formula (I) and a preparation method thereof. I In formula (R)1 And R2 Are each independently hydrogen. C1 -6 Alkyl and the like, R3 Document C3 -8 Cycloalkyl, R4 -SO2 - NRa Rb , SO2 - C1 -6 Alkyl group, SO2 - C3 -8 Cycloalkyl, SO2 - C1 -3 Alkylene - C3 -8 Cycloalkyl, SO2 - Rc , C1 -3 Alkylene - C (＝ O) O-C1 -6 Alkyl or - C1 -3 Alkylene - C (＝ O) - NRd Re , Ra , Rb , Rc , Rd And Re Having the meaning of the invention. The compound, the composition containing the compound and/or the preparation provided by the invention has good bactericidal activity and can be used as a bactericide in agriculture.

Synthesis, molecular modeling, selective aldose reductase inhibition and hypoglycemic activity of novel meglitinides

In the present study, a novel generation of selective aldose reductase ALR2 inhibitors with significant hypoglycemic activities was designed and modulated based on rhodanine scaffold joined to an acetamide linker in between two lipophilic moieties. The synthesis of the novel compounds was accomplished throughout simple chemical pathways. Molecular docking was performed on B-cell membrane protein SUR1, aldehyde reductase ALR1 and aldose reductase ALR2 active sites. Compounds 10B, 11B, 12B, 15C, 16C, 26F and 27F displayed the highest hypoglycemic activities with 80.7, 85.2, 87, 82.3, 83.5, 81.4 and 85.3% reduction in blood glucose levels, respectively. They were more potent than the standard hypoglycemic agent repaglinide with 65.4% reduction in blood glucose level. Compounds 12B and 15C with IC50 0.29 and 0.35 μM were more potent than the standard ALR2 inhibitor epalrestat with IC50 0.40 μM. They were selective towards ALR2 over ALR1 134 and 116 folds, respectively. Molecular docking studies matched with the in-vitro and in-vivo results to elucidate the dual activities of both compounds 12B and 15C as potent antagonists for ALR2 over ALR1 and good agonists for the SUR1 protein.

Design, synthesis and in silico insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities

Aiming to obtain an efficient anti-proliferative activity, structure- and ligand-based drug design approaches were expanded and utilized to design and refine a small compound library. Subsequently, thirty-two 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives were selected for synthesis based on the characteristic pharmacophoric features required for PI3K and B-Raf oncogenes inhibition. All the synthesized compounds were evaluated for their in vitro anticancer activity. Compounds 17 and 22c displayed an acceptable potent activity according to the DTP-NCI and were further evaluated in the NCI five doses assay. To validate our design, compounds with the highest mean growth inhibition percent were screened against the target PI3Kα and B-RafV600E to confirm their multi-kinase activity. The tested compounds showed promising multi-kinase activity. Compounds 17 and 22c anticancer effectiveness and multi-kinase activity against PI3Kα and B-RafV600E were consolidated by the inhibition of B-RafWT, EGFR and VEGFR-2 with IC50 in the sub-micromolar range. Further investigations on the most potent compounds 17 and 22c were carried out by studying their safety on normal cell line, in silico profiling and predicted ADME characteristics.

Synthesis and antimicrobial evaluations of sulfur inserted fluoro-benzimidazoles

A new series of fluorinated sulfur inserted benzimidazole analogues Za-i were synthesized and characterized. The new compounds were screened for their antimicrobial and antioxidant potential. The synthesized compounds were obtained by multiple step synthesis, initiating from the synthesis of 5-(difluoromethoxy)-1H-benzimidazole-2-thiol X. The compounds Ya-i prepared by reacting differently substituted anilines with chloroacetylchloride and triethylamine in DMF. Finally, the compound X was reacted with different derivatives of 2-chloro-N-phenylacetamide resulting in formation of titled compounds Za-i. The synthesized compounds (Za-Zi) were characterized by spectral analysis viz.1H & 13C NMR, mass spectra, elemental analysis and IR. The in vitro antimicrobial potential against Gram-positive (S. aureus and E. faecalis) and Gram-negative bacterial (E. coli and P.aeruginosa) strains as well as fungi (A. niger and C. albicans) was recorded for the obtained compounds. Some of the compounds exhibited encouraging results (in MIC) against Gram-positive and Gram-negative bacterial strains. These studies thus suggest that the designed sulfur inserted fluoro-benzimidazoles scaffold may serve as new promising template for further amplification as antimicrobial agents.

Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway

In order to find new and highly effective anti-tumor drugs with targeted therapeutic effects, a series of novel 4-aminoquinazoline derivatives containing N-phenylacetamide structure were designed, synthesized and evaluated for antitumor activity against four human cancer cell lines (H1975, PC-3, MDA-MB-231 and MGC-803) using MTT assay. The results showed that the compound 19e had the most potent antiproliferative activity against H1975, PC-3, MDA-MB-231 and MGC-803 cell lines. At the same time, compound 19e could significantly inhibit the colony formation and migration of H1975 cells. Compound 19e also arrested the H1975 cell cycle in the G1 phase and mediated cell apoptosis, promoted the accumulation of ROS in H1975 cells. Furthermore, compound 19e exerted antitumor effect in vitro by reducing the expression of anti-apoptotic protein Bcl-2 and increasing the pro-apoptotic protein Bax and p53. Mechanistically, compound 19e could significantly decreased the phosphorylation of EGFR and its downstream protein PI3K in H1975 cells. Which indicated that compound 19e targeted H1975 cell via interfering with EGFR-PI3K signaling pathway. Molecular docking showed that compound 19e could bind into the active pocket of EGFR. Those work suggested that compound 19e would have remarkable implications for further design of anti-tumor agents.

Preparation method and application of compounds BIA-01 and BIA-02 with CDC25B inhibitory activity

The invention relates to the field of medicine synthesis. The invention aims to solve the problems of insufficient drug targeting treatment precision, insufficient substituent group activity and poorbinding capacity with an acting part in the prior art. The invention discloses a preparation method and an application of compounds BIA-01 and BIA-02 with CDC25B inhibitory activity. The preparation method comprises the following steps: i, synthesis of 1a-(E)-N-(3-bromophenyl)-2-(oximido)acetamide; ii, synthesis of 2a-6-bromoindoline-2,3-diketone; iii, synthesis of a 3a,3b-N-chloroacetyl aniline derivative; iiii, synthesis of BIA-01, BIA-02-6-bromo-2,3-dioxoindoline-1-N-substituted phenyl acetamide. The compound BIA-01 and the compound BIA-02 which are high in antitumor activity and low in side effect are prepared, and the compounds have a high inhibition effect on tumors.

Design and synthesis of 2,4-dioxochroman-pyridinium-phenylacetamide derivatives as new anti-Alzheimer agents: in vitro and in silico studies

2,4-Dioxochroman-pyridinium-phenylacetamide derivatives 7a–n were synthesized and evaluated for their in vitro cholinesterase (ChE) inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Obtained results demonstrated that, among the synthesized compounds, two compounds, 7j and 7k, were more potent than the standard drug donepezil against BuChE and did not show cytotoxicity and carcinogenicity. Furthermore, through molecular modeling and molecular dynamic studies. we showed that these compounds can be located deep in the gorge cavity of BuChE and that they interacted with catalytic residues, acyl, and cholin-binding pockets of this enzyme. Support information.

Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib

Thiazolidinedione (TZD) has been an interesting scaffold due to its proven antidiabetic activity and encouraging findings in anticancer drug discovery. We synthesised benzylidene thiazolidinedione derivatives which exhibited excellent antiproliferative effects in chronic myeloid leukemic cells K562 and the most active compounds 3t and 3x had GI50 value of 0.9 and 0.23 μM respectively. Both the compound was found to arrest the growth of K562 cells in G0/G1 phase in a time and dose dependent manner. Further, western blot analysis revealed that 3t and 3x could also inhibit the expression of cell proliferation markers, PCNA and Cyclin D1 and compound 3x up-regulated apoptosis markers, cleaved PARP1 and activated caspase 3, which could be a possible mechanism for the excellent antiproliferative effects exhibited by these compounds. In vitro combination studies of 3t and 3x with Imatinib found to potentiate the antitumor effects of Imatinib. Further in vivo efficacy in K562 xenografts, of 3t and 3x alone and in combination with Imatinib was found to be promising and far better than control group and combination treatment was found to be more effective as compared to only Imatinib treated or test compound treated animals. Thus, our findings suggest that these compounds are promising antitumor agents and could help to enhance the anticancer effects of Imatinib and other tyrosine kinase inhibitors, when used in combination.

Halogen-substituted triazolethioacetamides as a potent skeleton for the development of metallo-β-lactamase inhibitors

Metallo-β-lactamases (MβLs) are the target enzymes of β-lactam antibiotic resistance, and there are no effective inhibitors against MβLs available for clinic so far. In this study, thirteen halogen-substituted triazolethioacetamides were designed and synthesized as a potent skeleton of MβLs inhibitors. All the compounds displayed inhibitory activity against ImiS with an IC50 value range of 0.032–15.64 μM except 7. The chlorine substituted compounds (1, 2 and 3) inhibited NDM-1 with an IC50 value of less than 0.96 μM, and the fluorine substituted 12 and 13 inhibited VIM-2 with IC50 values of 38.9 and 2.8 μM, respectively. However, none of the triazolethioacetamides exhibited activity against L1 at inhibitor concentrations of up to 1 mM. Enzyme inhibition kinetics revealed that 9 and 13 are mixed inhibitors for ImiS with Ki values of 0.074 and 0.27μM using imipenem as the substrate. Docking studies showed that 1 and 9, which have the highest inhibitory activity against ImiS, fit the binding site of CphA as a replacement of ImiS via stable interactions between the triazole group bridging ASP120 and hydroxyl group bridging ASN233.

Synthesis and molecular modeling of novel non-sulfonylureas as hypoglycemic agents and selective ALR2 inhibitors

Novel non-sulfonylureas derivatives bearing an acetamide linker between a spirohydantoin scaffold and a phenyl ring were prepared and their hypoglycemic activity was estimated in vivo. Their abilities to discriminate in vitro between aldehyde reductase (A